A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT06707883 Phase 2 ACTIVE_NOT_RECRUITING

To evaluate the efficacy and safety of TQC2731 injection in patients with moderate to severe chronic obstructive pulmonary disease.

Details

Lead sponsor	Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase	Phase 2
Status	ACTIVE_NOT_RECRUITING
Enrolment	258
Start date	2024-12-31
Completion	2027-09

Conditions

• Chronic Obstructive Pulmonary Disease

Interventions

• TQC2731 injection
• TQC2731 Placebo

Primary outcomes

• Annual rate of acute COPD exacerbation — Baseline to week 24
  Annualized rate of moderate or severe COPD exacerbations over the 24-week treatment period compared to placebo

Countries

China